Atai Life Sciences BV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company, which engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health.

atai Life Sciences launches TryptageniX to further expand atai's robust intellectual property portfolio and strengthen atai's supply chain

COMPASS Pathways

Cybin

Ameri Holdings

Field Trip Health Ltd

GH Research PLC

Jaguar Health

Mind Medicine MindMed

Seelos Therapeutics

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.

9 Psychedelic Stocks to Watch For 2022

Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pathways (NASDAQ:CMPS), a drug developer looking to accelerate patient access to psilocybin therapy for treatment-resistant depression. In recent days, Atai Life Sciences (Compass' biggest shareholder) increased its ownership in Compass Pathways buying another 619,095 shares, taking its stake in the company from 19.4 to 20.8 percent.

Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways

Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q3 2021 Results - Earnings Call Transcript

-Positive topline results from COMP360's Phase 2b study-

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.

Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update.

atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November:

atai Life Sciences to Participate in Upcoming November Investor Conferences

Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O'Leary and Peter Thiel recognizing the potential in the psych drug industry.  Psychedelic drugs, such as psilocybin mushrooms and LSD, were once seen merely as a way for college students and concert goers to escape reality or at least enhance it.

This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop

Their clinical programs and research-enabling technologies both surpass the competition.

These 4 Psychedelic Biotech Stocks Are Leading the Pack

atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care

atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change

Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression and other mental health indications.

What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders

Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout.  PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications.

Atai Life Launches Depression-Focused Firm

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement (“Loan Agreement”) with strategic partner IntelGenx Technologies Corp. (“IntelGenx”) to support IntelGenx's conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock Exchange (“TSX”). Completion of the uplisting and the commencement of trading of IntelGenx's common shares, 8% convertible debentures with a maturity date of June 30, 2022, and share purchase warrants expiring on February 11, 2023 is subject to the satisfaction by IntelGenx of all of the final conditions of listing.

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx's Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate. The study will evaluate the safety and efficacy of a proprietary formulation of arketamine that could have a similar therapeutic action to ketamine in the treatment of depression, with less dissociative effects.

Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine

NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine being developed for therapeutic treatment of psychiatric disorders such as Treatment Resistant Depression (TRD). The Phase 2a clinical trial has received the necessary regulatory and ethics approvals to initiate the study.

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences  (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. (“Introspect”), today announced a usability study of Introspect's digital therapeutic (DTx) app technology in support of standard of care ketamine therapy for patients with treatment resistant depression (TRD) in collaboration with Kadima Neuropsychiatry. TRD impacts 100 million people globally, close to a third of the 300 million diagnosed with depression, many of whom are geographically restricted in their ability to access in-person psychological care.

atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.

Time to Buy the Magic Stocks? Magic Mushrooms, That Is.

Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q2 2021 Results - Earnings Call Transcript

-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters' over-allotment-

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

Talkspace

They're the first pioneers in exciting new markets.

3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge

BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences  (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences (Revixia), a wholly owned subsidiary developing Salvinorin A (SalA) to treat a variety of mental health disorders.

atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

Atai Life Sciences (NASDAQ:ATAI) has announced the launch of a new subsidiary that will research Salvinorin A, the active compound in salvia divinorum, a hallucinogenic herb native to Central America. Atai, based in Berlin, is developing a variety of psychedelic treatments for mental health purposes.

Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary

BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update.

atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update

BERLIN, Aug. 06, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity Growth Conference, to be held virtually from August 10-12, 2021.

News for Atai Life Sciences BV Stock (ATAI)